arginase1

Numidargistat dihydrochloride (CB-1158 dihydrochloride) is an orally active and highly effective arginase (ARG1) inhibitor, an immuno-oncology agent that inhibits TGF-β2-induced subcapsular cataract by reducing the proliferation of lens epithelial cells (LEC) and decreasing the expression of fibronectin, α-SMA, collagen 1A1, and vimentin.

L-Ornithine ((S)-2, 5-diaminopentanoic acid) is a non-protein amino acid. L-Ornithine is mainly used in the urea cycle to remove excess nitrogen from the body. L-Ornithine is renoprotective. L-Ornithine has antifatigue effects.

Urea (Carbonyldiamide) is formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end metabolite of protein catabolism and accounts for about one-half of the total urinary solids.

Piceatannol 3'-O-glucoside (Piceatannol 3-glycoside) increases pulmonary blood oxygen tension and decreases pulmonary interstitial edema, so it can protect lung injury.

OATD-02 is an orally active, competitive, reversible, noncovalent inhibitor with slow offset kinetics that targets both Arginase1 and Arginase2, exhibiting inhibitory concentrations (IC50) of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1). Notably, OATD-02 mitigates tumor immunosuppression provoked by these arginases and has potential application in melanoma research [1].

OATD-02 hydrochloride is the hydrochloride salt form of OATD-02. It is an orally effective, competitive, reversible, and non-covalent dual inhibitor of Arginase1 and Arginase2. OATD-02 hydrochloride serves as a sustained-release inhibitor that efficiently blocks the activity of intracellular arginases, with IC50 values of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1). It effectively eliminates tumor-induced immunosuppression caused by both types of arginases. This compound is utilized in research studies on melanoma.